JPS63243878A - Detection of lipid metabolism abnormality - Google Patents
Detection of lipid metabolism abnormalityInfo
- Publication number
- JPS63243878A JPS63243878A JP8035987A JP8035987A JPS63243878A JP S63243878 A JPS63243878 A JP S63243878A JP 8035987 A JP8035987 A JP 8035987A JP 8035987 A JP8035987 A JP 8035987A JP S63243878 A JPS63243878 A JP S63243878A
- Authority
- JP
- Japan
- Prior art keywords
- lipoprotein
- lipid metabolism
- blood
- abnormality
- apo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037356 lipid metabolism Effects 0.000 title claims abstract description 26
- 230000005856 abnormality Effects 0.000 title claims abstract description 21
- 238000001514 detection method Methods 0.000 title claims abstract description 6
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 40
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 40
- 210000004369 blood Anatomy 0.000 claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 15
- 150000002632 lipids Chemical class 0.000 claims description 9
- 230000006371 metabolic abnormality Effects 0.000 claims description 9
- 108010012071 Lipoprotein-X Proteins 0.000 abstract description 11
- 210000002966 serum Anatomy 0.000 abstract description 3
- 210000002381 plasma Anatomy 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 66
- 235000012000 cholesterol Nutrition 0.000 description 19
- 230000002159 abnormal effect Effects 0.000 description 9
- 102000006410 Apoproteins Human genes 0.000 description 6
- 108010083590 Apoproteins Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000926 separation method Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
【発明の詳細な説明】 ｌ至ユ！」月１立１ 本発明は、新規な脂質代謝異常の検出方法に関する。[Detailed description of the invention] L to you! ” Monthly 1st 1st The present invention relates to a novel method for detecting abnormal lipid metabolism.
従来の技術及びその問題点
脂質代謝異常は、リポ蛋白質の合成、分泌及び異化の過
程において、このいずれかに異常をぎたした状態であり
、先天性リポ蛋白質代謝異常と後天性リポ蛋白質代謝異
常とがある。Conventional techniques and their problems Lipid metabolism abnormalities are conditions in which there is an abnormality in any of the processes of lipoprotein synthesis, secretion, and catabolism, and are divided into congenital lipoprotein metabolic abnormalities and acquired lipoprotein metabolic abnormalities. There is.
脂質代謝異常は、種々の疾患、例えば心筋梗塞等の心疾
患、脳卒中等の脳血管障害等の各種動脈硬化性疾患等の
発生の重大な危険因子（リスクファクター〉であり、又
斯かる疾患の進展、予後等に重大な影響を及ぼす。従っ
て、脂質代謝異常の検出は、各種の臨床検査乃至診断に
おいて、極めて重要である。Abnormal lipid metabolism is an important risk factor for the occurrence of various diseases, such as heart diseases such as myocardial infarction, cerebrovascular disorders such as stroke, and various arteriosclerotic diseases. It has a significant impact on the progression, prognosis, etc. Therefore, detection of lipid metabolism abnormalities is extremely important in various clinical tests and diagnoses.
従来、脂質代謝異常の検出は、血液中の総コレステロー
ル値をパラメーターとするのが最も一般に定容している
。即ち、血液中の総コレステロール値の正常域が臨床的
及び経験的に設定されており、斯かる域値を逸脱するも
のを脂質代謝異常として検出している。また、近年、脂
質とアポ蛋白質とが結合して存在している血液中のリポ
蛋白質を比重により分画し特に高比重リポ蛋白質（ＨＤ
Ｌ）中のコレステロール値を測定し、この１−ＩＯＬ−
コレステロール値自体やｌ−Ｉ Ｄ Ｌ−コレステロー
ル値に対する総コレステロール中のｌ−Ｉ Ｄ Ｌ−コ
レステロール以外のコレステロール値の比である所謂動
脈硬化指数を、上記総コレステロール値の場合と同様に
して、脂質代謝異常の検出のパラメーターとすることも
行なわれている。Conventionally, lipid metabolism abnormalities have been most commonly detected using the total cholesterol level in the blood as a parameter. That is, a normal range for the total cholesterol level in the blood has been set clinically and empirically, and anything that deviates from this range is detected as a lipid metabolic disorder. In addition, in recent years, lipoproteins in the blood, which exist in combination with lipids and apoproteins, have been fractionated by specific gravity, and in particular, high-density lipoproteins (HD
Measure the cholesterol level in L), and measure the cholesterol level in this 1-IOL-
The so-called arteriosclerosis index, which is the ratio of the cholesterol value other than l-I D L-cholesterol in the total cholesterol to the cholesterol value itself or l-I D L-cholesterol value, is calculated in the same manner as for the total cholesterol value above. It is also being used as a parameter for detecting metabolic abnormalities.
しかしながら、現在までに蓄積された多くの疫学的調査
の結果及び臨床的知見によれば２等従来の脂質代謝異常
の検出方法は、実際の脂質代謝異常を必ずしも的確に反
映しておらず、殊に臨床上その意義が低いことが往々に
して指摘されている。However, according to the results of many epidemiological studies and clinical findings accumulated to date, the conventional methods for detecting lipid metabolism abnormalities do not necessarily accurately reflect actual lipid metabolic abnormalities. It is often pointed out that the clinical significance is low.
即ち、総コレステロール値をパラメーターとする方法に
ついては、その方法により検出される脂質代謝異常即ち
総コレステロール値の高値は虚血性心疾患のリスクファ
クターの一つとしての意義は有するものの（例えばＨｅ
ｄ、Ｃｌ１ｎ、Ｎｏｒｔｈ Ａｍ、、 ５８゜３６３−
３７９（１９７４）等）、必ずしも疾患と結付いておら
ず、その検出方法による脂質代謝正常群における疾患発
生成いは高度脂質代謝異常群における恒常的な健全性等
は、何れも何ら希なものでは無い。That is, regarding the method that uses total cholesterol level as a parameter, although abnormal lipid metabolism detected by this method, that is, high total cholesterol level, has significance as one of the risk factors for ischemic heart disease (for example, He
d, Cl1n, North Am,, 58°363-
379 (1974), etc.), are not necessarily linked to disease, and depending on the detection method, the occurrence of disease in a group with normal lipid metabolism or the constant health of a group with severe lipid metabolism abnormality are both rare. Not so.
また、ＨＤＬ−コレステロール値や動脈硬化指数をパラ
メーターとする方法も、上記と同様に、実際の脂質代謝
異常を必ずしも的確に反映するものでは無い（動脈硬化
、１４（４）、９３１−９３６（１９８Ｇ）等）。Furthermore, the method using HDL-cholesterol levels and arteriosclerosis index as parameters does not necessarily accurately reflect actual lipid metabolism abnormalities (Arteriosclerosis, 14(4), 931-936 (198G )etc).
斯かる現状において、実際の脂質代謝異常を的確に反映
しており、該異常をより有効に検出し得る新規なパラメ
ーターの開発が斯界、殊に疾患の発見、進展並びに治療
効果等の的確な把握を意図する臨床分野において、強く
要望されている。Under these circumstances, the development of new parameters that accurately reflect actual lipid metabolic abnormalities and can detect these abnormalities more effectively is of great importance in this field, especially for accurate understanding of disease discovery, progression, and treatment effects. There is a strong demand for this in the clinical field.
問題点を解決する為の手段
本発明者は、上記要望に応えるべく、脂質代謝異常の把
握に際し特にアポ蛋白質に管間した研究を重ねてきた。Means for Solving the Problems In order to meet the above-mentioned needs, the present inventors have conducted repeated research on apoproteins in particular in understanding lipid metabolic abnormalities.
その研究過程において、アポ蛋白質の違いによって分画
される特定のリポ蛋白質が脂質代謝異常を検出するため
のパラメーターとして極めて有効であることを見出した
。本発明は、斯かる新たな知見に基づいて完成されたも
のである。In the course of this research, we discovered that specific lipoproteins that are fractionated based on differences in apoproteins are extremely effective as parameters for detecting abnormalities in lipid metabolism. The present invention was completed based on this new knowledge.
即ち本発明は、血液中絶リポ蛋白質の内、アポＡｍＩ含
有リポ蛋白質及びアポＢ−１００含有リポ蛋白質以外の
リポ蛋白質を測定して脂質代謝異常を検出することを特
徴とする脂質代謝異常の検出方法に係る。That is, the present invention provides a method for detecting abnormal lipid metabolism, which comprises detecting abnormal lipid metabolism by measuring lipoproteins other than apoAmI-containing lipoproteins and apoB-100-containing lipoproteins among blood abortive lipoproteins. Pertains to.
本発明は、血液中絶リポ蛋白質の内、アポＡ−■含有リ
ポ蛋白質及びアポＢ−１００含有リポ蛋白質以外のリポ
蛋白質（以下、これをリポ蛋白質Ｘという）を測定し、
これを脂質代謝異常の新規なパラメーターとして該異常
を検出するものである。即ち、リポ蛋白質Ｘは、脂質代
謝が正常の場合は殆んど存在しないが、脂質代謝異常の
程度に応じてその存在色が増加し、該異常を的確に反映
しており、これにより該異常を検出できるものである。The present invention measures lipoproteins other than apoA-■-containing lipoproteins and apoB-100-containing lipoproteins (hereinafter referred to as lipoprotein
This is used as a new parameter for detecting abnormalities in lipid metabolism. In other words, lipoprotein can be detected.
本発明において、検体とする血液としては、空腹時のも
のが好ましく、血清又は血漿として用いるのが好ましい
。In the present invention, the blood sample is preferably fasting blood, and preferably serum or plasma.
本発明において測定するリポ蛋白質Ｘとしては、リポ蛋
白質Ｘの総量に限られず、リポ蛋白質Ｘに対応するもの
であれば良い。即ち、血液中のリポ蛋白質は、コレステ
ロール、トリグリセリド、リン脂質、遊離脂肪酸等の脂
質とアポ蛋白質とが結合して存在しているのであるから
、リポ蛋白質Ｘとしては、その総量１その脂質の何れか
又は全部、そのアポ蛋白質の総量等を何れも用いること
ができる。これらの内、リポ蛋白質Ｘのコレステロール
値を用いるのが好ましい。The lipoprotein X measured in the present invention is not limited to the total amount of lipoprotein X, but may be any one that corresponds to lipoprotein X. In other words, lipoproteins in the blood exist in combination with apoproteins and lipids such as cholesterol, triglycerides, phospholipids, and free fatty acids. The total amount of apoprotein, or the total amount of apoprotein, can be used. Among these, it is preferable to use the cholesterol value of lipoprotein X.
以下、コレステロール値を用いる場合について説明する
。Hereinafter, the case where cholesterol value is used will be explained.
リポ蛋白質Ｘのコレステロール値は、分離されたリポ蛋
白質Ｘを用いて、通常の手段、例えば酵素法等により測
定することができる。リポ蛋白質Ｘの分離は、特に限定
はないが、好ましい方法として抗アポＡ−Ｉ抗体及び抗
アポＢ−１００抗体のアフイニテイクロマトグラフイー
による手段を採用した分離法を例示できる。斯かるリポ
蛋白質Ｘの分離は、血漿若しくは血清又はそのリポ蛋白
質両分を、上記両者のアフイニテイ力ラムに順次付すこ
とにより、それらの非吸着画分（アフイニテイを示さな
い両分）として容易に収得することができる。また、上
記リポ蛋白質Ｘのコレステロール値は、上記において分
離されるアポＡ−Ｉ含有リポ蛋白質（吸着画分）及びア
ポＢ−１００含有リポ蛋白質（吸着画分）の夫々のコレ
ステロール値を加算した値を血漿（勿論血清又はリポ蛋
白質画分でも良い。以下同じ。）総コレステロール値か
ら差引くことによっても求めることができる。The cholesterol level of lipoprotein X can be measured using separated lipoprotein Although there are no particular limitations on the separation of lipoprotein Such separation of lipoprotein can do. Furthermore, the cholesterol value of lipoprotein It can also be determined by subtracting the total cholesterol value from plasma (of course, serum or lipoprotein fractions may also be used; the same applies hereinafter).
血漿総コレステロール値の測定は、通常の手段例えば酵
素法等により行なえば良い。The plasma total cholesterol level may be measured by conventional means such as an enzyme method.
ここで、重要なことは血液中のリポ蛋白質Ｘのコレステ
ロール値を測定することであり、斯かる測定の為の手段
には何らの制限も無いことである。What is important here is to measure the cholesterol level of lipoprotein X in the blood, and there are no restrictions on the means for such measurement.
而して、本発明において、脂質代謝異常の検出の為のパ
ラメーターとしてリポ蛋白質Ｘのコレステロール値をそ
のまま用いることも可能であるが、本発明者は該異常を
特に的確に反映するパラメーターとして該コレステロー
ル値を血漿総コレステロール値当りの比として算出した
ものが好ましいことを見出した。この場合の算出式とし
ては、例えば下記式（Ｉ）を好ましいものとして例示で
きる。Therefore, in the present invention, although it is possible to use the cholesterol value of lipoprotein It has been found that it is preferable to calculate the value as a ratio to the plasma total cholesterol value. As a calculation formula in this case, for example, the following formula (I) can be exemplified as a preferable one.
但し、Ａは血漿総コレステロール値（、ｍｇ／旧）を、
Ｂは血漿から分離したアポＡ−Ｉ含有リポ蛋白質のコレ
ステロール値（ｍｇ／旧）を、Ｃは血漿から分離したア
ポＢ−１００含有リポ蛋白質のコレステロール値（Ｉｎ
（１／旧）を夫々示す。However, A is the plasma total cholesterol level (mg/old),
B is the cholesterol value (mg/old) of apoA-I-containing lipoprotein isolated from plasma, and C is the cholesterol value of apoB-100-containing lipoprotein isolated from plasma (In
(1/old) are shown respectively.
発明の効果
本発明によれば、リポ蛋白質Ｘを測定し、これを脂質代
謝異常のパラメーターとして該異常を容易且つ有効に検
出できる。即ち、リポ蛋白質Ｘは、脂質代謝が正常の場
合は殆んど存在しないが、脂質代謝異常の程度に応じて
その存在量が増加し、該異常を的確に反映している。従
って、本発明により脂質代謝異常を検出することは、前
記各種疾患の発見、進展並びに治療効果等の的確な把握
に極めて有用である。本発明の方法は、特に心筋梗塞等
の心疾患や肥満等の病態把握に極めて優れており、従来
の検出方法では把握し得なかったものも充分に把握し得
る。Effects of the Invention According to the present invention, lipoprotein X can be measured and used as a parameter for abnormal lipid metabolism to easily and effectively detect the abnormality. That is, lipoprotein Therefore, detecting lipid metabolism abnormalities according to the present invention is extremely useful for accurately understanding the discovery, progress, and therapeutic effects of the various diseases mentioned above. The method of the present invention is particularly excellent in understanding pathological conditions such as heart diseases such as myocardial infarction and obesity, and can sufficiently understand conditions that could not be detected using conventional detection methods.
実施例
以下、実施例を挙げて、本発明を更に具体的に説明する
。EXAMPLES Hereinafter, the present invention will be explained in more detail with reference to Examples.
実施例１
（１） 健常者２０名（平均年齢２７オ）より空腹時Ｅ
ＤＴＡ採血し、常法に従い血漿を得た。Example 1 (1) Fasting E from 20 healthy subjects (average age 27 months)
DTA blood was collected and plasma was obtained according to a conventional method.
各血漿について血漿総コレステロール値をヨーダイト法
（Ｉｏｄｉｄｅ法、ｒＨｅｒｋｏ ｔｅｓｔ ＣＨＯＪ
、関東化学■製）により測定した。Plasma total cholesterol levels were determined for each plasma using the Iodide method (rHerko test CHOJ).
, manufactured by Kanto Kagaku ■).
（２） 次に、上記各血漿の０．２５ｍ１を抗アポＡ−
Ｉ抗体結合アフイニテイ力ラム（［アポカラムＡ−ＩＪ
、鈎日本抗体研究所製、カラム容ｆｆ！１ｍ１）に付
し、洗浄液（０，０１ＭＰｈｏｓｐｈａｔｅ Ｂｕｆｆ
ｅｒｅｄ ５ａｌｉｎｅ、 ｌ） ８７ 、２ ） ２
０１を加えて洗浄した。次いで、０．５ＭＮａＣｌ含有
１Ｍ酢酸緩衝液７．５ｍｌでカラムに吸着した両分を溶
出させ、得られた溶出液を半回の３．５Ｍトリス水溶液
にて中和して、アポＡ−Ｉ含有リポ蛋白質を得た。該リ
ポ蛋白質のコレステロール値を上記（１）に従い測定し
た。(2) Next, 0.25ml of each of the above plasma was added to anti-apoA-
I antibody binding affinity column ([apocolumn A-IJ
, manufactured by Nippon Antibody Research Institute, column capacity ff! 1ml) and washing solution (0.01MP Phosphate Buff
ered 5aline, l) 87, 2) 2
01 was added for washing. Next, both fractions adsorbed on the column were eluted with 7.5 ml of 1 M acetate buffer containing 0.5 M NaCl, and the resulting eluate was neutralized with half a 3.5 M Tris aqueous solution to remove Apo A-I. Lipoproteins were obtained. The cholesterol level of the lipoprotein was measured according to (1) above.
（３） 次に、カラムとして抗アポＢ−１００抗体結合
アフイニテイ力ラム（「アポカラムＢ−１００」、鈎日
本抗体研究所製、カラム容置１ｍ１）を用い、溶出液口
を１０ｍ１とする以外は上記（２）と同様にしてアポＢ
−１００含有リポ蛋白質のコレステロール値を測定した
。(3) Next, an anti-apo B-100 antibody-binding affinity column (“Apo Column B-100”, manufactured by Kagi Nippon Antibody Institute, column capacity 1 ml) was used as a column, except that the eluate port was set to 10 ml. Appointment B in the same way as in (2) above.
The cholesterol value of -100-containing lipoprotein was measured.
（４） 上記（１）〜（３）で得られた各コレステロー
ルＷｉ （ｍｇ／ｍｌ ）より、前述の式（Ｉ＞に従い
パラメーターを算出した。(4) From each cholesterol Wi (mg/ml) obtained in (1) to (3) above, parameters were calculated according to the above formula (I>).
結果を第１図に示す。該図より、健常者においては、リ
ポ蛋白質Ｘが殆んど存在しない（パラメーターが０％に
近くなる）ことが判る。ちなみに、上記健常者は、既知
のパラメーター（血漿総コレステロール値；１３０〜１
７０ｍｆｌ／ｍｌ ＞によっても脂質代謝異常の認めら
れない者である。The results are shown in Figure 1. The figure shows that in healthy subjects, lipoprotein X is almost absent (the parameter is close to 0%). By the way, the above healthy subjects had known parameters (plasma total cholesterol level; 130-1
70mfl/ml > 70 mfl/ml, no abnormal lipid metabolism was observed.
実施例２
実施例１に従って、本発明方法による脂質代謝異常の無
いことが確認された健常者８名（平均年齢２６オ）につ
いての、斯かるパラメーターの経時変動を調べた。Example 2 According to Example 1, changes over time in the parameters of eight healthy subjects (average age 26 months) who were confirmed to have no lipid metabolic abnormalities by the method of the present invention were investigated.
結果を第２図に示す。該図より経時変動は非常に少ない
ことが判る。The results are shown in Figure 2. It can be seen from the figure that there is very little variation over time.
実施例３
健常者５２名（平均年齢２７オ）より空腹時ＥＤＴＡ採
血し、常法に従い血漿を得た。各血漿について血漿総コ
レステロール値を前記酵素法により測定し、血漿総コレ
ステロール値が１００〜１５０ｍｏ／旧の１９名をΔ群
、同１５０〜２００ｍｇ／ｄｌ （７） ２６名をＢ群
、同２００〜２５０ｍａ／旧の７名を０群と夫々群分け
した。Example 3 Fasting EDTA blood was collected from 52 healthy subjects (average age 27 months), and plasma was obtained according to a conventional method. The plasma total cholesterol value of each plasma was measured by the enzymatic method described above, and 19 patients with a plasma total cholesterol value of 100 to 150 mo/old were placed in the Δ group, 150 to 200 mg/dl (7). The 7 participants of 250ma/old were divided into 0 group and 0 group respectively.
次に、実施例１と同様にしてパラメーターを求めた。Next, parameters were determined in the same manner as in Example 1.
結果を第３図に示す。該図より、このパラメーターは、
血漿総コレステロール値に無関係であり、健常者であれ
ば、はぼ一定の範囲内の値を示すことが明らかである。The results are shown in Figure 3. From the figure, this parameter is
It is clear that it is unrelated to the plasma total cholesterol level, and that a healthy person exhibits a value within a fairly constant range.
実施例４
心疾患患者４３名について、実施例１と同様にしてパラ
メーターを求めた。Example 4 Parameters were determined in the same manner as in Example 1 for 43 heart disease patients.
結果を第４図に示す。第３図の健常者における［パラメ
ーターの平均値＋２ＸＳＤＪが１９％であることから、
パラメーター値の２０％以上を脂質代謝異常と設定する
ことにより、第４図より、血漿総コレステロール値１５
０〜２００ ｍｇ／ｍｌの群についてパラメーター２０
％以上の５例、２００〜２５０ ｍｇ／ｍｌの群につい
てパラメーター２０％以上の４例について、夫々血漿総
コレステロール値では把握し得ない脂質代謝異常を充分
に把握し得た。The results are shown in Figure 4. Since the average value of parameters + 2XSDJ in healthy subjects in Figure 3 is 19%,
By setting 20% or more of the parameter value as abnormal lipid metabolism, from Figure 4, the plasma total cholesterol value 15
Parameter 20 for the group 0-200 mg/ml
% or more, and in 4 cases in the 200-250 mg/ml group where the parameter was 20% or more, it was possible to fully understand lipid metabolic abnormalities that could not be detected by plasma total cholesterol values.
実施例５
上記実施例４における患者の薬剤治療（「ロレルコ」、
大球製薬■製）前後のパラメーターの変動を実施例１に
従って調べた。Example 5 Drug treatment of the patient in Example 4 above (“Lorelco”,
The changes in parameters before and after (manufactured by Daikyu Seiyaku ■) were investigated according to Example 1.
結果を第５図に示す。該図より、治療によりパラメータ
ーが明確に低下し、脂質代謝異常が顕著に改善されたこ
とが判り、病態の把握に極めて有用であることが明らか
である。The results are shown in Figure 5. From the figure, it can be seen that the parameters clearly decreased and the abnormal lipid metabolism was significantly improved by the treatment, and it is clear that the treatment is extremely useful for understanding the pathological condition.
実施例６
肥満者（３０才、女性、身長１５０ｃｍ、体重１００ｋ
ｇ）の食事療法前後におけるパラメーターの変動を実施
例１に従って調べた。結果を第６図に示す。体重が９５
．５ｋＧに減少する等の肥満病態の改善に伴い、パラメ
ーターの明らかな低下が認められた。Example 6 Obese person (30 years old, female, height 150 cm, weight 100 kg)
Changes in parameters before and after g) dietary therapy were investigated according to Example 1. The results are shown in Figure 6. Weight is 95
．． A clear decrease in the parameters was observed with the improvement of the obesity condition, such as a decrease to 5kG.
第１図〜第６図は、健常者及び患者についての各実施例
で得られたパラメーターを示すグラフである。
（以 上）
第１図
第２図
月
第３図
Ａ君羊 Ｂｎ Ｃ君手第６図
４事療；去Ｆｊ 童車、療し吾ｒ支手
続補正書印発）
昭和６３年６月２４日
１ 事件の表示
昭和６２年特許願第８０３５９号
２ 発明の名称
脂質代謝異常の検出方法
３ 補正をする者
事件との関係 特許出願人
株式会社日本抗体研究所
４代理人
自 発
６ 補正の対象
明細書中「発明の詳細な説明」の項
補正の内容
１ 明細書第６頁第１４行に「特に限定はないが」とあ
るを「特に限定はなく、公知の分離法に従って行なうこ
とができる。」と訂正する。
２ 明細書第６頁第１７〜１８行に「分離法を・・・・
・・の分離は、」とあるを「分離法又はバッチ法等を例
示できる。アフィニティクロマトグラフィーを用いた方
法によれば、斯かるリポ蛋白質Ｘは、」と訂正する。
（以 上）FIGS. 1 to 6 are graphs showing parameters obtained in each example for healthy subjects and patients. (Above) Figure 1, Figure 2, Figure 3, Figure 3, A, Bn, C, Figure 6, 4, 2013; 1 Indication of the case Patent Application No. 80359 of 1985 2 Name of the invention Method for detecting abnormalities in lipid metabolism 3 Relationship with the case by the person making the amendment Patent applicant Japan Antibody Institute Co., Ltd. 4 Sponsored by the agent 6 Details subject to the amendment Contents of Amendment 1 in the "Detailed Description of the Invention" section of the specification On page 6, line 14 of the specification, the phrase "although there is no particular limitation" was replaced with "there is no particular limitation, and the separation can be carried out according to any known separation method." ” he corrected. 2. On page 6 of the specification, lines 17-18, ``Separation method...
The phrase "... can be separated by a separation method or a batch method. According to a method using affinity chromatography, such lipoprotein (that's all)
Claims (1)
白質及びアポＢ−１００含有リポ蛋白質以外のリポ蛋白
質を測定して脂質代謝異常を検出することを特徴とする
脂質代謝異常の検出方法。(1) Detection of lipid metabolism abnormalities characterized by detecting lipid metabolic abnormalities by measuring lipoproteins other than apoA-I-containing lipoproteins and apoB-100-containing lipoproteins among total lipoproteins in blood. Method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62080359A JP2657225B2 (en) | 1987-03-31 | 1987-03-31 | Methods for detecting abnormal lipid metabolism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62080359A JP2657225B2 (en) | 1987-03-31 | 1987-03-31 | Methods for detecting abnormal lipid metabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63243878A true JPS63243878A (en) | 1988-10-11 |
| JP2657225B2 JP2657225B2 (en) | 1997-09-24 |
Family
ID=13716059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62080359A Expired - Lifetime JP2657225B2 (en) | 1987-03-31 | 1987-03-31 | Methods for detecting abnormal lipid metabolism |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2657225B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5417863A (en) * | 1992-09-24 | 1995-05-23 | Perseptive Biosystems, Inc. | Quantitative measurement of LDL |
| JP2005504277A (en) * | 2001-09-14 | 2005-02-10 | アラン クラインフェルド、 | Diagnostic markers for ischemia |
| US7241861B2 (en) | 2001-05-15 | 2007-07-10 | Japan Immunoresearch Laboratories Co., Ltd. | High density lipoprotein-reactive peptides |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55159158A (en) * | 1979-05-31 | 1980-12-11 | Wako Pure Chem Ind Ltd | Novel reagent for separation of lipoprotein |
| JPS57161551A (en) * | 1981-03-30 | 1982-10-05 | Kokusai Shiyaku Kk | Reagent for separation of lipoprotein x and determining method for it |
| JPS58210000A (en) * | 1982-05-31 | 1983-12-07 | Nippon Chemiphar Co Ltd | Determination of concentration of lipoprotein cholesterol |
-
1987
- 1987-03-31 JP JP62080359A patent/JP2657225B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55159158A (en) * | 1979-05-31 | 1980-12-11 | Wako Pure Chem Ind Ltd | Novel reagent for separation of lipoprotein |
| JPS57161551A (en) * | 1981-03-30 | 1982-10-05 | Kokusai Shiyaku Kk | Reagent for separation of lipoprotein x and determining method for it |
| JPS58210000A (en) * | 1982-05-31 | 1983-12-07 | Nippon Chemiphar Co Ltd | Determination of concentration of lipoprotein cholesterol |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5417863A (en) * | 1992-09-24 | 1995-05-23 | Perseptive Biosystems, Inc. | Quantitative measurement of LDL |
| US7241861B2 (en) | 2001-05-15 | 2007-07-10 | Japan Immunoresearch Laboratories Co., Ltd. | High density lipoprotein-reactive peptides |
| JP2005504277A (en) * | 2001-09-14 | 2005-02-10 | アラン クラインフェルド、 | Diagnostic markers for ischemia |
| JP2010223972A (en) * | 2001-09-14 | 2010-10-07 | Alan Kleinfeld | Diagnostic marker for ischemia |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2657225B2 (en) | 1997-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dahlen et al. | Association of levels of lipoprotein Lp (a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. | |
| Koba et al. | Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases | |
| Goff Jr et al. | Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study | |
| Jurgens et al. | Lipoprotein (a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke | |
| Krempler et al. | Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein B | |
| Stenvinkel et al. | Apo (a)-isoform size, nutritional status and inflammatory markers in chronic renal failure | |
| Nishiyama et al. | Asymmetric dimethylarginine (ADMA) as a possible risk marker for ischemic stroke | |
| Young et al. | Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins. | |
| Pickup et al. | Serum sialic acid concentration and coronary heart disease in NIDDM | |
| Tallaksen et al. | Thiamin and thiamin phosphate ester deficiency assessed by high performance liquid chromatography in four clinical cases of Wernicke encephalopathy | |
| Gylling et al. | Physiologic mechanisms for reduced apolipoprotein AI concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. | |
| Smaoui et al. | Lipids and lipoprotein (a) concentrations in Tunisian type 2 diabetic patients: relationship to glycemic control and coronary heart disease | |
| Goswami et al. | Apo-B/apo-AI ratio: a better discriminator of coronary artery disease risk than other conventional lipid ratios in Indian patients with acute myocardial infarction | |
| Patsch et al. | Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia | |
| Widmann et al. | Lipoprotein (a): a risk factor for peripheral vascular disease | |
| Berlit et al. | Serum lipids and anticonvulsants | |
| Rifai et al. | Review of serum lipids and apolipoproteins in risk-assessment of coronary heart disease | |
| Superko et al. | High-density lipoprotein cholesterol measurements: A help or hindrance in practical clinical medicine? | |
| Oh et al. | Platelet-activating factor in plasma of patients with sickle cell disease in steady state | |
| Quattrone et al. | A hypofibrinolytic state in overweight patients with cerebral venous thrombosis and isolated intracranial hypertension | |
| JPS63243878A (en) | Detection of lipid metabolism abnormality | |
| Tamura et al. | Serum lipoprotein (a) concentrations are related to coronary disease progression without new myocardial infarction. | |
| Verges et al. | Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM | |
| Urakami et al. | Lp (a) lipoprotein in cerebrovascular disease and dementia | |
| Korpilahti et al. | Components of the insulin resistance syndrome are associated with progression of atherosclerosis in non-grafted arteries 5 years after coronary artery bypass surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |